Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anacor Pharmaceuticals has signed a license agreement with Schering-Plough for the development and commercialization of an anti-fungal therapy currently in phase II trials.
Subscribe to our email newsletter
The drug, AN2690, is designed to treat onychomycosis, a fungal infection of the nail and nail bed, that affects seven to 10% of the US population.
Under the terms of the agreement, Anacor will receive a $40 million upfront payment and a $10 million financing commitment from Schering-Plough. The company is eligible to receive payments potentially exceeding $575 million for development, regulatory and commercial milestones.
In addition, Anacor will receive royalty payments on future sales. Schering-Plough will assume all costs for the drug’s development and Anacor retains an option to co-promote the drug in the US.
AN2690 is currently being evaluated in three fully-enrolled phase II studies. Results to date have shown that the drug is well tolerated and highly potent, with patients who received the treatment demonstrating significant clear nail growth.